Compare ASTRAZENECA PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FRESENIUS KABI ONCO. ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 117.1 22.1 529.0% View Chart
P/BV x 35.8 3.1 1,151.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,278176 726.1%   
Low Rs88379 1,124.3%   
Sales per share (Unadj.) Rs228.437.7 606.1%  
Earnings per share (Unadj.) Rs10.45.1 203.5%  
Cash flow per share (Unadj.) Rs16.36.7 241.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.842.5 232.2%  
Shares outstanding (eoy) m25.00158.23 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 140.1%   
Avg P/E ratio x104.225.0 417.2%  
P/CF ratio (eoy) x66.418.9 351.0%  
Price / Book Value ratio x10.93.0 365.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00820,135 134.1%   
No. of employees `0001.41.2 117.7%   
Total wages/salary Rs m1,535703 218.3%   
Avg. sales/employee Rs Th4,210.95,176.2 81.4%   
Avg. wages/employee Rs Th1,132.2610.4 185.5%   
Avg. net profit/employee Rs Th191.1699.6 27.3%   
INCOME DATA
Net Sales Rs m5,7105,963 95.8%  
Other income Rs m12318 680.6%   
Total revenues Rs m5,8335,981 97.5%   
Gross profit Rs m4631,430 32.4%  
Depreciation Rs m147258 57.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m4381,216 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m179342 52.3%   
Profit after tax Rs m259806 32.2%  
Gross profit margin %8.124.0 33.8%  
Effective tax rate %40.828.1 145.2%   
Net profit margin %4.513.5 33.6%  
BALANCE SHEET DATA
Current assets Rs m3,2095,102 62.9%   
Current liabilities Rs m2,0702,385 86.8%   
Net working cap to sales %20.045.6 43.8%  
Current ratio x1.62.1 72.5%  
Inventory Days Days72150 48.2%  
Debtors Days Days35113 30.8%  
Net fixed assets Rs m7905,148 15.4%   
Share capital Rs m50158 31.6%   
"Free" reserves Rs m2,4196,556 36.9%   
Net worth Rs m2,4696,732 36.7%   
Long term debt Rs m0952 0.0%   
Total assets Rs m4,60510,388 44.3%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.6 216.0%   
Return on assets %5.67.5 74.9%  
Return on equity %10.512.0 87.6%  
Return on capital %17.714.6 121.5%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m3005,298 5.7%   
Fx outflow Rs m2,0151,772 113.7%   
Net fx Rs m-1,7153,525 -48.7%   
CASH FLOW
From Operations Rs m881,274 6.9%  
From Investments Rs m-94-1,204 7.8%  
From Financial Activity Rs mNA-196 0.0%  
Net Cashflow Rs m-6-126 4.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 15.7 9.6 163.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   12,856 42,599 30.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS